Dutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.
https://european-biotechnology.com/wp-content/uploads/2024/04/coins-1726618_1920.jpg12791920Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2021-07-15 07:00:002021-07-15 07:00:00€26m financing for ISA Pharmaceuticals
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-07-13 11:19:172021-07-13 11:19:17Nordic Nanovector with Interim CEO
Danish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-07-06 11:45:002021-07-06 11:45:00Azafaros appoints Stefano Portolano as CEO
Nanosyrinx raises £6.2m to validate drug delivery platform
Latest NewsCoventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
€26m financing for ISA Pharmaceuticals
Latest NewsDutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.
Unilever licences Arzeda Inc.s enzyme technology
Latest NewsAs part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Nordic Nanovector with Interim CEO
AppointmentsMalene Brondberg, Chief Financial Officer of Nordic Nanovector since May 2020, became Interim Chief Executive Officer of the company.
Novo Nordisk invests in amyloidosis pipeline
Latest NewsDanish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Sanofi invests heavily in multiple myeloma pipeline
Latest NewsSanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
Bio-Me raises NOK10m
Latest NewsOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Drug repurposing trends shorten timelines
Sponsored PublicationsThis white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Azafaros appoints Stefano Portolano as CEO
AppointmentsDr Stefano Portolano, M.D., is the new Chief Executive Officer of Azafaros and has been appointed to the Board of Directors of the Dutch company.
NFL Biosciences goes public, raises €5m
Latest NewsFrench biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.